Press releaseGlobe Newswire
Nkarta
NKTX · NASDAQ
$1.74−$0.01 (−0.57%)TodayMarket closed ·
Prev close $1.75
Latest news
- Press releaseGlobe Newswire
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
- Press releaseGlobe Newswire
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
- Press releasePRNewswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
- Press releaseGlobe Newswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
- Press releaseGlobe Newswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
- Press releasePRNewswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
- Press releasePRNewswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
- Press releaseGlobe Newswire
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
- Press releaseGlobe Newswire
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
- Press releaseGlobe Newswire
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
- Press releaseGlobe Newswire
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
- NewsVandana Singh
Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsVandana Singh
Why Is Autoimmune Disease Focused Nkarta Stock Trading Higher On Thursday?
- NewsAvi Kapoor
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
- NewsAvi Kapoor
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
- NewsAvi Kapoor
Why Serve Robotics Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.